Burden of RSV in Young Children in High-Income Countries: Incidence Estimates From a Multilevel Meta-Analysis in Primary and Emergency Care
Abstract
Background: Most respiratory syncytial virus (RSV) infections in children are managed in primary care settings, including ambulatory care and emergency departments (EDs). This study provides adjusted pooled RSV incidence estimates for children under 5 years in primary care settings in high-income countries (HICs).
Methods: We used population-based RSV incidence rates from 27 studies collected in a previous systematic review as input parameters. To adjust for heterogeneity in study design, we assessed the impact of four key factors: 1) age, 2) primary care setting (ambulatory care or EDs), 3) data collection period (year-round or seasonal), and 4) study methodology (cohort studies with laboratory-confirmed RSV, healthcare databases, surveillance data). In the final model, we corrected for age, primary care setting, and study methodology. Adjusted pooled RSV incidence estimates were calculated using a multilevel logit-logistic regression model.
Results: For children < 5 years, the adjusted pooled RSV incidence estimate in primary care settings was 62.8 per 1000 population (95% CI 45.3-86.6). Incidence was higher in ambulatory care (108.1 per 1000; 95% CI 78.0-148.0) compared to EDs (35.8 per 1000; 95% CI 25.3-50.3). Age-stratified incidence estimates declined with increasing age, showing 86.5 (95% CI 61.6-120.2), 80.3 (95% CI 57.1-111.8), 60.7 (95% CI 43.2-84.6), and 36.5 (95% CI 25.4-52.2) per 1000 for children aged < 6 months, 0-1 year, 0-2 years, and 0-5 years,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,000 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.